Skip to main content

Table 2 Characteristics according to pathologic reports in patients with gray zone PSA levels

From: 68Ga-PSMA PET/CT-based multivariate model for highly accurate and noninvasive diagnosis of clinically significant prostate cancer in the PSA gray zone

 

Non-CSPCa

CSPCa

P value

Mean age (SD), y

63.23 (6.71)

65.14 (5.87)

0.204

Median PSA (IQR), ng/ml

6.29 (5.24–7.95)

7.61 (5.34–9.21)

0.206

Median PV (IQR), ml

49.66 (32.90-68.05)

31.40 (21.69–37.32)

< 0.001*

Median PSAD (IQR), ng/ml2

0.13 (0.09–0.17)

0.21 (0.17–0.29)

< 0.001*

Median FPSA/TPSA (IQR)

0.16 (0.13–0.22)

0.12 (0.09–0.15)

0.001*

MRI results

  

0.005*

PI-RADS 1–2

23 (44.2%)

4 (13.8%)

 

PI-RADS 3–5

29 (55.8%)

25 (86.21%)

 

68Ga-PSMA PET/CT results

  

< 0.001*

Negative

40 (76.92%)

2 (6.90%)

 

Positive

12 (23.08%)

27 (93.10%)

 

SUVmax

3.75 (3.20–6.20)

8.20 (6.50–12.70)

< 0.001*

  1. CSPCa, clinically significant prostate cancer; SD, standard deviation; PSA, prostate-specific antigen; IQR, interquartile range; PV, prostate volume; PSAD, prostate-specific antigen density; TPSA, total prostate-specific antigen; FPSA, free prostate-specific antigen; MRI, magnetic resonance imaging; PI-RADS, Prostate Imaging-Reporting and Data System; 68Ga-PSMA PET/CT, 68Ga-labeled prostate-specific membrane antigen positron emission tomography/computed tomography; SUVmax, maximum standardized uptake values
  2. * p < 0.05
Back to article page

Cancer Imaging

ISSN: 1470-7330

Contact us